Exhibit 10.1


 


 





CHINA BIOLOGIC PRODUCTS, INC.


DIRECTOR AGREEMENT


 


THIS AGREEMENT (The “Agreement”)
is made on March 4, 2015 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter referred to as
the “Company”), and Mr. Min Fang (hereinafter referred to as the “Director”).


 


BACKGROUND


 


The Board of Directors
of the Company desires to appoint the Director to fill an existing vacancy due to resignation of Mr. Dai Feng and to have the Director
perform the duties of a director and the Director desires to be so appointed for such position and to perform the duties required
of such position in accordance with the terms and conditions of this Agreement.


 


AGREEMENT


 


In consideration for
the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged,
the Company and the Director hereby agree as follows:


 


1.DUTIES.
The Company requires that the Director be available to perform the duties of a director customarily related to this function as
may be determined and assigned by the Board of Directors of the Company and as may be required by the Company’s constituent
instruments, including its certificate or articles of incorporation, bylaws and its corporate governance and board committee charters,
each as amended or modified from time to time, and by applicable law, including by the Delaware General Corporation Law (the “DGCL”).
The Director agrees to devote as much time as is necessary to perform completely the duties as the Director of the Company. The
Director will perform such duties described herein in accordance with the general fiduciary duty of directors arising under the
DGCL.


 


2.TERM.
The term of this Agreement shall commence as of the date of the Director’s appointment by the Board of Directors of the Company
and shall continue until the Director’s removal or resignation.


 


3.COMPENSATION. The
Director waives any right to compensation in connection with the services provided hereunder.


 


4.EXPENSES.
The Company will reimburse the Director for pre-approved reasonable business related expenses incurred in good faith in the performance
of the Director’s duties for the Company. Such payments shall be made by the Company upon submission by the Director of a
signed statement itemizing the expenses incurred. Such statement shall be accompanied by sufficient documentary matter to support
the expenditures.


 


5.CONFIDENTIALITY.
The Company and the Director each acknowledge that, in order for the intents and purposes of this Agreement to be accomplished,
the Director shall necessarily be obtaining access to certain confidential information concerning the Company and its affairs,
including, but not limited to business methods, information systems, financial data and strategic plans which are unique assets
of the Company (“Confidential Information”). The Director covenants not to, either directly or indirectly, in
any manner, utilize or disclose to any person, firm, corporation, association or other entity any Confidential Information.


 






    	 



    	 



    

 


 


6.NON-COMPETE.
During the term of this Agreement (the “Restricted Period”), the Director shall not, directly or indirectly,
(i) in any manner whatsoever engage in any capacity with any business competitive with the Company’s current lines of business
or any business then engaged in by the Company, any of its subsidiaries or any of its affiliates (the “Company's Business”)
for the Director’s own benefit or for the benefit of any person or entity other than the Company or any subsidiary or affiliate;
or (ii) have any interest as owner, sole proprietor, shareholder, partner, lender, director, officer, manager, employee, consultant,
agent or otherwise in any business competitive with the Company's Business; provided, however, that (x) this Clause
6 shall not be deemed to prohibit any investment activities of Warburg Pincus LLC and its affiliated funds and the Director’s
activities in connection therewith, provided further that the Director cannot act as a director in any company engaging in business
similar to or competing with the Company’s Business without the Company’s written consent, and (y) the Director may
hold, directly or indirectly, solely as an investment, not more than two percent (2%) of the outstanding securities of any person
or entity which are listed on any national securities exchange or regularly traded in the over-the-counter market notwithstanding
the fact that such person or entity is engaged in a business competitive with the Company's Business.


 


7.TERMINATION.
With or without cause, the Company and the Director may each terminate this Agreement at any time upon ten (10) days written notice,
and the Company shall be obligated to pay to the Director the compensation and expenses due up to the date of the termination.
Nothing contained herein or omitted herefrom shall prevent the shareholder(s) of the Company from removing the Director with immediate
effect at any time for any reason.


 


8.INDEMNIFICATION.
The Company shall indemnify, defend and hold harmless the Director, to the full extent allowed by the law of the State of Delaware,
and as provided by, or granted pursuant to, any charter provision, bylaw provision, agreement (including, without limitation, the
Indemnification Agreement executed herewith), vote of stockholders or disinterested directors or otherwise, both as to action in
the Director’s official capacity and as to action in another capacity while holding such office. The Company and the Director
are executing the Indemnification Agreement in the form attached hereto as Exhibit A.


 


9.EFFECT
OF WAIVER. The waiver by either party of the breach of any provision of this Agreement shall not operate as or be construed
as a waiver of any subsequent breach thereof.


 


10.NOTICE. Any and
all notices referred to herein shall be sufficient if furnished in writing at the addresses specified on the signature page hereto
or, if to the Company, to the Company’s address as specified in filings made by the Company with the U.S. Securities and
Exchange Commission and if by fax to +8610 6598 3222.


 






    	2



    	 



    




 


11.GOVERNING
LAW. This Agreement shall be interpreted in accordance with, and the rights of the parties hereto shall be determined by, the
laws of the State of New York without reference to that state’s conflicts of laws principles.


 


12.ASSIGNMENT.
The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder
shall inure to the benefit of, and be enforceable by or against, its successors and assigns. The duties and obligations of the
Director under this Agreement are personal and therefore the Director may not assign any right or duty under this Agreement without
the prior written consent of the Company.


 


13.MISCELLANEOUS.
If any provision of this Agreement shall be declared invalid or illegal, for any reason whatsoever, then, notwithstanding such
invalidity or illegality, the remaining terms and provisions of the this Agreement shall remain in full force and effect in the
same manner as if the invalid or illegal provision had not been contained herein.


 


14.ARTICLE
HEADINGS. The article headings contained in this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.


 


15.COUNTERPARTS.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one instrument.
Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes.


 


16.ENTIRE
AGREEMENT. Except as provided elsewhere herein, this Agreement sets forth the entire agreement of the parties with respect
to its subject matter and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or
warranties, whether oral or written, by any officer, employee or representative of any party to this Agreement with respect to
such subject matter.


 


 


[Signature Page Follows]




    	3



    	 



    

IN WITNESS WHEREOF,
the parties hereto have caused this Director Agreement to be duly executed and signed as of the day and year first above written. 


 


 


	 	CHINA
BIOLOGIC PRODUCTS, INC.
	 	 
	 	By: 	/s/ David (Xiaoying) Gao	 
	 	Name:  David (Xiaoying) Gao

                    Title:  Chairman & Chief Executive Officer

	 	                 	 
	 	 	 



  


	 	DIRECTOR
	 	 
	 	By: 	/s/ Min Fang	 
	 	Name:  Min Fang

                    

	 	 	 
	 	Address: 	 
	 	 	 
	 	 	 





 





 


 




    	4



    	 



    

EXHIBIT A


 


Form of Indemnification Agreement


 


(See Attached)








    	5